Peregrine Pharma (PPHM) Starts 2015 Right with Strong Bavituximab in HCC Data - Roth Capital
Tweet Send to a Friend
Roth Capital affirms Peregrine Pharma (Nasdaq: PPHM) at Buy with a price target of $5 after the company announced the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
